Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Clobazam in Subjects With Lennox-Gastaut Syndrome

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Lundbeck LLC
ClinicalTrials.gov Identifier:
NCT00162981
First received: September 9, 2005
Last updated: January 6, 2012
Last verified: January 2012

September 9, 2005
January 6, 2012
October 2005
August 2006   (final data collection date for primary outcome measure)
  • Percent Reduction in Number of Drop Seizures. [ Time Frame: 4-week baseline period and 4-week maintenance period ] [ Designated as safety issue: No ]
    Number of drop seizures (average per week) was obtained from seizure diaries. The average drop in seizures per week for patients who did not complete the maintenance period was calculated based on the time from the beginning of the maintenance period to date of withdrawal.
  • A Comparison of the High Dose Group to Low Dose Group of the Percent Reduction in Number of Drop Seizures. [ Time Frame: 4-week baseline period and the 4-week maintenance period ] [ Designated as safety issue: No ]
    Number of drop seizures (average per week) was obtained from seizure diaries. The average drop in seizures per week for patients who did not complete the maintenance period was calculated based on the time from the beginning of the maintenance period to date of withdrawal.
Percent reduction in number of drop seizures from the baseline period compared to the maintenance period.
Complete list of historical versions of study NCT00162981 on ClinicalTrials.gov Archive Site
  • Percent of Patients Considered Treatment Responders Defined as Those With a >= 25%, >= 50%, >= 75%, and 100% Reduction in Drop Seizures. [ Time Frame: 4-week baseline period and 4-week maintenance period ] [ Designated as safety issue: No ]
    Number of drop seizures (average per week) was obtained from seizure diaries. The average drop in seizures per week for patients who did not complete the maintenance period was calculated based on the time from the beginning of the maintenance period to date of withdrawal.
  • Parent/Caregiver Global Evaluations of the Patient's Overall Change in Symptoms. [ Time Frame: Week 3 ] [ Designated as safety issue: No ]
    The parent/caregiver was asked to rate the patient's overall change in symptoms and overall change in seizure activity and Quality of Life since the beginning of clobazam treatment by checking "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse".
  • Parent/Caregiver Global Evaluations of the Patient's Overall Change in Symptoms. [ Time Frame: Week 7 ] [ Designated as safety issue: No ]
    The parent/caregiver was asked to rate the patient's overall change in symptoms and overall change in seizure activity and Quality of Life since the beginning of clobazam treatment by checking "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse".
  • Percent of subjects considered treatment responders defined as those with a >/= 25%, >/= 50%, >/= 75% reduction in drop seizures from the baseline period compared to the maintenance period.
  • Parent/Caregiver global evaluations of seizure activity and quality of life.
Not Provided
Not Provided
 
Clobazam in Subjects With Lennox-Gastaut Syndrome
Safety and Efficacy of Clobazam in Subjects With Lennox-Gastaut Syndrome

The purpose of this study is to evaluate the safety and efficacy of clobazam as adjunctive therapy in the treatment of seizures which lead to drop attacks (drop seizures) in subjects 2 to 30 years of age with Lennox-Gastaut Syndrome (LGS). Subjects will be enrolled at approximately 10 investigational sites in the U.S. for up to 15 weeks. Subjects will be randomly assigned to either a low dose or a high dose. The study will include a baseline period, a titration period and a maintenance period. After the maintenance period, subjects will either continue into an open-label extension study or enter the taper period with a final visit 1 week after the last dose.

LGS poses a significant treatment challenge. While antiepileptic medications are the mainstay of treatment, no one antiepileptic drug (AED) provides satisfactory relief for all or most patients with LGS and a combination of treatments is often required. Many patients with LGS are refractory to standard AED treatment.

More effective and better tolerated treatment options are needed for this population of medically intractable epilepsy patients. Clobazam is unique in that it is the only non-1, 4-benzodiazepine used in the treatment of epilepsy.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
  • Epilepsy
  • Epilepsy, Generalized
  • Seizures
  • Drug: Clobazam Low Dose
    5 to 10 mg/day with doses in the morning and at bedtime; orally
    Other Name: Onfi™
  • Drug: Clobazam High Dose
    5 to 40 mg/day with doses in the morning and at bedtime; orally
    Other Name: Onfi™
  • Experimental: Clobazam Low Dose
    Intervention: Drug: Clobazam Low Dose
  • Experimental: Clobazam High Dose
    Intervention: Drug: Clobazam High Dose
Conry JA, Ng YT, Paolicchi JM, Kernitsky L, Mitchell WG, Ritter FJ, Collins SD, Tracy K, Kormany WN, Abdulnabi R, Riley B, Stolle J. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia. 2009 May;50(5):1158-66. Epub 2008 Dec 15.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
68
October 2006
August 2006   (final data collection date for primary outcome measure)

Key Inclusion Criteria:

  • Subject must have been <11 years of age at the onset of LGS
  • Subject must have LGS
  • Subject must be on at least 1 stable dose AED
  • Parent or caregiver must be able to keep an accurate seizure diary

Key Exclusion Criteria:

  • Etiology of subject's seizures is a progressive neurologic disease. Subjects with tuberous sclerosis will not be excluded from study participation
  • Subject has had an episode of status epilepticus within 12 weeks of baseline
  • Subject has had an anoxic episode requiring resuscitation within 1 year of screening
  • Subject has had a clinically significant history of an allergic reaction or significant sensitivity to benzodiazepines
  • Subject is taking more than 3 concurrent AEDs. Note: Vagal Nerve Stimulation (VNS) or ketogenic diet is allowed and each will be counted as one of the three allowed AEDs
  • If the subject is on the ketogenic diet, has been for less than 4 weeks prior to screening or suffers from frequent stooling
  • If the subject has a VNS, the settings have not been stable for at least 4 weeks prior to screening
  • Subject has taken corticotropins in the 6 months prior to screening
  • Subject is currently taking long-term systemic steroids (excluding inhaled medication for asthma treatment) or any other daily medication known to exacerbate epilepsy. An exception will be made of prophylactic medication, for example, for urinary tract infections or asthma
  • If the subject is taking felbamate, has been taking it for less than 1 year prior to screening or previous treatment with felbamate resulted in withdrawal due to liver or bone marrow adverse events
Both
2 Years to 30 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00162981
13108A, OV1002
Yes
Lundbeck LLC
Lundbeck LLC
Not Provided
Study Director: Email contact via H. Lundbeck A/S LundbeckClinicalTrials@lundbeck.com
Lundbeck LLC
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP